|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2004-12-27
|
|
pubmed:abstractText |
Gemcitabine has broad activity in a variety of solid tumors including biliary tract carcinomas. The authors evaluated 6-month survival, response, and toxicity associated with a combination of gemcitabine, 5-fluorouracil (5-FU), and leucovorin (LV) in patients with unresectable or metastatic biliary tract or gallbladder adenocarcinoma (ACA).
|
|
pubmed:grant |
http://linkedlifedata.com/resource/pubmed/grant/CA-15083,
http://linkedlifedata.com/resource/pubmed/grant/CA-25224,
http://linkedlifedata.com/resource/pubmed/grant/CA-35101,
http://linkedlifedata.com/resource/pubmed/grant/CA-35103,
http://linkedlifedata.com/resource/pubmed/grant/CA-35195,
http://linkedlifedata.com/resource/pubmed/grant/CA-35415,
http://linkedlifedata.com/resource/pubmed/grant/CA-35448,
http://linkedlifedata.com/resource/pubmed/grant/CA-37404,
http://linkedlifedata.com/resource/pubmed/grant/CA-37417,
http://linkedlifedata.com/resource/pubmed/grant/CA-52352,
http://linkedlifedata.com/resource/pubmed/grant/CA-60276,
http://linkedlifedata.com/resource/pubmed/grant/CA-63826,
http://linkedlifedata.com/resource/pubmed/grant/CA-63848,
http://linkedlifedata.com/resource/pubmed/grant/CA-63849
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
pubmed-author:Al-KhatibHaniH,
pubmed-author:AlbertsSteven RSR,
pubmed-author:BurgartLawerenceL,
pubmed-author:CeraPeter JPJ,
pubmed-author:FinchTom RTR,
pubmed-author:FlynnPatrick JPJ,
pubmed-author:KnostJames AJA,
pubmed-author:LevittRalphR,
pubmed-author:MahoneyMichelle RMR,
pubmed-author:TschetterLoren KLK,
pubmed-author:WindschitlHarold EHE
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
103
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
111-8
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:15558814-Adenocarcinoma,
pubmed-meshheading:15558814-Adult,
pubmed-meshheading:15558814-Aged,
pubmed-meshheading:15558814-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15558814-Biliary Tract Neoplasms,
pubmed-meshheading:15558814-Cholangiocarcinoma,
pubmed-meshheading:15558814-Deoxycytidine,
pubmed-meshheading:15558814-Female,
pubmed-meshheading:15558814-Fluorouracil,
pubmed-meshheading:15558814-Gallbladder Neoplasms,
pubmed-meshheading:15558814-Humans,
pubmed-meshheading:15558814-Infusions, Intravenous,
pubmed-meshheading:15558814-Injections, Intravenous,
pubmed-meshheading:15558814-Leucovorin,
pubmed-meshheading:15558814-Male,
pubmed-meshheading:15558814-Middle Aged,
pubmed-meshheading:15558814-Survival Analysis
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
|
|
pubmed:affiliation |
Division of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA. alberts.steven@mayo.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Multicenter Study,
Clinical Trial, Phase II
|
